Clinical Study of Evaluating the Safety and Initial Efficacy of XS005 Injection Combined With Stupp Regimen for Adjuvant Chemotherapy in Subjects With Primary Glioblastoma(GBM)
Latest Information Update: 01 Nov 2024
At a glance
- Drugs Temozolomide (Primary) ; XS 005 XellSmart Biomedical Suzhou (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
Most Recent Events
- 29 Oct 2024 Status changed from recruiting to suspended.
- 13 Feb 2024 New trial record